Novel Treatment Options in Mantle Cell Lymphoma With Gilles Salles, MD, PhD

 An aggressive form of B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a challenging disease to treat, with a median overall survival of 6 to 7 years. Even in patients who achieve a complete response, recurrence and relapse are still frequent. In this episode of Oncology Data Advisor, Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, joins i3 Health for a discussion that covers the efficacy of newly developed Bruton tyrosine kinase (BTK) inhibitor and chimeric antigen receptor (CAR) T-cell therapies, the management of adverse events associated with these treatments, updates on ongoing research, and advice for clinicians as they seek to optimize outcomes for patients with MCL.

Related Posts

By accepting you will be accessing a service provided by a third-party external to


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.